Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Neoplasms of the CNS

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 108 articles:
HTML format
Text format



Single Articles


    May 2018
  1. ZHANG Y, Ishida CT, Ishida W, Lo SL, et al
    Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and elicits Synthetic Lethality in Glioblastoma.
    Clin Cancer Res. 2018 May 15. pii: 1078-0432.CCR-18-0260.
    PubMed     Text format     Abstract available


    April 2018
  2. WILDES TJ, Grippin A, Dyson KA, Wummer BM, et al
    Cross-talk between T cells and hematopoietic stem cells during adoptive cellular therapy for malignant glioma.
    Clin Cancer Res. 2018 Apr 30. pii: 1078-0432.CCR-17-3061.
    PubMed     Text format     Abstract available


  3. GEDEON PC, Schaller TH, Chitneni SK, Choi BD, et al
    A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma.
    Clin Cancer Res. 2018 Apr 27. pii: 1078-0432.CCR-17-0126.
    PubMed     Text format     Abstract available


  4. KESARWANI P, Prabhu A, Kant S, Kumar P, et al
    Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0041.
    PubMed     Text format     Abstract available


  5. JACKSON CM, Lim M
    Immunotherapy for glioblastoma: playing chess, not checkers.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0491.
    PubMed     Text format     Abstract available


  6. MARTINEZ-RICARTE F, Mayor R, Martinez-Saez E, Rubio-Perez C, et al
    Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumour DNA from cerebrospinal fluid.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-17-3800.
    PubMed     Text format     Abstract available


    March 2018
  7. SAHA D, Wakimoto H, Peters CW, Antoszczyk SJ, et al
    Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1717.
    PubMed     Text format     Abstract available


  8. WORONIECKA KI, Rhodin KE, Chongsathidkiet P, Keith KA, et al
    T-Cell Dysfunction in Glioblastoma: Applying a New Framework.
    Clin Cancer Res. 2018 Mar 28. pii: 1078-0432.CCR-18-0047.
    PubMed     Text format     Abstract available


  9. DETTLING S, Stamova S, Warta R, Schnolzer M, et al
    Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-cell Targets in Human IDH-Mutant Glioma.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-1839.
    PubMed     Text format     Abstract available


  10. NAKASHIMA H, Nguyen T, Kasai K, Passaro C, et al
    Toxicity and efficacy of a novel GADD34-expressing oncolytic HSV-1 for the treatment of experimental glioblastoma.
    Clin Cancer Res. 2018 Mar 6. pii: 1078-0432.CCR-17-2954.
    PubMed     Text format     Abstract available


  11. LADOMERSKY E, Zhai L, Lenzen A, Lauing KL, et al
    IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3573.
    PubMed     Text format     Abstract available


    February 2018
  12. NISHIYAMA A, Yamada T, Kita K, Wang R, et al
    Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-1623.
    PubMed     Text format     Abstract available


  13. LI XN, Kogiso M, Qi L, Braun FK, et al
    Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX models.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-2256.
    PubMed     Text format     Abstract available


  14. MOHME M, Schliffke S, Maire CL, Runger A, et al
    Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
    Clin Cancer Res. 2018 Feb 14. pii: 1078-0432.CCR-17-2617.
    PubMed     Text format     Abstract available


  15. HOLLON TC, Orringer DA
    Shedding light on IDH1 mutation in gliomas.
    Clin Cancer Res. 2018 Feb 13. pii: 1078-0432.CCR-18-0011.
    PubMed     Text format     Abstract available


  16. WORONIECKA K, Chongsathidkiet P, Rhodin KE, Kemeny HR, et al
    T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma.
    Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-1846.
    PubMed     Text format     Abstract available


  17. GORDON RE, Zhang L, Peri S, Kuo YM, et al
    Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2923.
    PubMed     Text format     Abstract available


  18. KABRAJI S, Ni J, Lin N, Xie S, et al
    Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3351.
    PubMed     Text format     Abstract available


    January 2018
  19. GOMEZ S, Garrido-Garcia A, Garcia-Gerique L, Lemos I, et al
    A novel method for rapid molecular subgrouping of medulloblastoma.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-2243.
    PubMed     Text format     Abstract available


  20. NIMMERVOLL B, Boulos N, Bianski BM, Dapper J, et al
    Establishing A Preclinical Multidisciplinary Board for Brain Tumors.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2168.
    PubMed     Text format     Abstract available


    December 2017
  21. PAL J, Patil V, Kumar A, Kaur K, et al
    Loss-of-function mutations in Calcitonin receptor (CALCR) identify highly aggressive glioblastoma with poor outcome.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1901.
    PubMed     Text format     Abstract available


  22. UCKERMANN O, Juratli TA, Galli R, Conde M, et al
    Optical analysis of glioma: Fourier-transform infrared spectroscopy reveals the IDH1 mutation status.
    Clin Cancer Res. 2017 Dec 19. pii: 1078-0432.CCR-17-1795.
    PubMed     Text format     Abstract available


  23. SU YT, Chen R, Wang H, Song H, et al
    Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Clin Cancer Res. 2017 Dec 18. pii: 1078-0432.CCR-17-2032.
    PubMed     Text format     Abstract available


  24. JIN X, Jin X, Kim LJY, Dixit D, et al
    Inhibition of ID1-BMPR2 intrinsic signaling sensitizes glioma stem cells to differentiation therapy.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1529.
    PubMed     Text format     Abstract available


    November 2017
  25. CHANG K, Bai HX, Zhou H, Su C, et al
    Residual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging.
    Clin Cancer Res. 2017 Nov 22. pii: clincanres.2236.2017.
    PubMed     Text format     Abstract available


  26. WEISS T, Schneider H, Silginer M, Steinle A, et al
    NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma.
    Clin Cancer Res. 2017 Nov 21. pii: clincanres.1766.2017.
    PubMed     Text format     Abstract available


  27. MIGLIORINI D, Dietrich PY, Stupp R, Linette GP, et al
    CAR-T cell Therapies in Glioblastoma: a first look.
    Clin Cancer Res. 2017 Nov 20. pii: clincanres.2871.2017.
    PubMed     Text format     Abstract available


  28. NANDHU MS, Behera P, Bhaskaran V, Longo SL, et al
    Development of a function-blocking antibody against fibulin-3 as targeted reagent for glioblastoma.
    Clin Cancer Res. 2017 Nov 16. pii: clincanres.1628.2017.
    PubMed     Text format     Abstract available


  29. CHEN Q, Cai J, Wang Q, Wang Y, et al
    Long non-coding RNA NEAT1, regulated by the EGFR pathway, contributes to glioblastoma progression through the WNT/beta-Catenin pathway by scaffolding EZH2.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0605.2017.
    PubMed     Text format     Abstract available


  30. WICK W, Kessler T
    Drug repositioning meets precision in glioblastoma.
    Clin Cancer Res. 2017 Nov 13. pii: clincanres.2989.2017.
    PubMed     Text format     Abstract available


    October 2017
  31. BYRON SA, Tran NL, Halperin RF, Phillips JJ, et al
    Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma.
    Clin Cancer Res. 2017 Oct 26. pii: clincanres.0963.2017.
    PubMed     Text format     Abstract available


  32. ACERBI F, Broggi M, Schebesch KM, Hohne J, et al
    Fluorescein-guided surgery for resection of high-grade gliomas: A multicentric prospective phase II study (FLUOGLIO).
    Clin Cancer Res. 2017 Oct 10. pii: clincanres.1184.2017.
    PubMed     Text format     Abstract available


    September 2017
  33. AVRIL T, Etcheverry A, Pineau R, Obacz J, et al
    CD90 expression controls migration and predicts dasatinib response in glioblastoma.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1549.2017.
    PubMed     Text format     Abstract available


  34. LI J, Wu J, Bao X, Honea N, et al
    Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients using an IVIVE-PBPK Modeling Approach.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.0983.2017.
    PubMed     Text format     Abstract available


  35. MULLER-GREVEN GM, Carlin C, Burgett ME, Ahluwalia MS, et al
    Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0249.2017.
    PubMed     Text format     Abstract available


  36. CHOI SH, Stuckey DW, Pignatta S, Reinshagen C, et al
    Tumor resection boosts therapeutic efficacy of encapsulated stem cells expressing a highly secretable variant of interferon-beta in glioblastomas.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0077.2017.
    PubMed     Text format     Abstract available


    August 2017
  37. FELSBERG J, Hentschel B, Kaulich K, Gramatzki D, et al
    Prognostic role of Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.0890.2017.
    PubMed     Text format     Abstract available


  38. ALEXANDER BM, Ba S, Berger MS, Berry DA, et al
    Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0764.2017.
    PubMed     Text format     Abstract available


  39. OLMEZ I, Brenneman B, Xiao A, Serbulea V, et al
    Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0803.2017.
    PubMed     Text format     Abstract available


  40. WANG G, Shen J, Sun J, Jiang Z, et al
    Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/beta-catenin Signaling.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0774.2017.
    PubMed     Text format     Abstract available


    July 2017
  41. ZHANG CB, Cheng W, Ren X, Wang Z, et al
    Tumor Purity As an Underlying Key Factor in Glioma.
    Clin Cancer Res. 2017 Jul 28. pii: clincanres.2598.2016.
    PubMed     Text format     Abstract available


  42. ZHAI L, Ladomersky E, Lauing KL, Wu M, et al
    Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0120.2017.
    PubMed     Text format     Abstract available


  43. PATEL SH, Poisson LM, Brat DJ, Zhou Y, et al
    T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower Grade Gliomas: A TCGA/TCIA Project.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0560.2017.
    PubMed     Text format     Abstract available


  44. OIZEL K, Chauvin C, Oliver L, Gratas C, et al
    Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity.
    Clin Cancer Res. 2017 Jul 18. pii: clincanres.3102.2016.
    PubMed     Text format     Abstract available


  45. FAN QW, Nicolaides TP, Weiss WA
    Inhibiting 4EBP1 in glioblastoma.
    Clin Cancer Res. 2017 Jul 10. pii: clincanres.0042.2017.
    PubMed     Text format     Abstract available


  46. CANELLA A, Welker AM, Yoo JY, Xu J, et al
    Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide Against Malignant Gliomas.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3151.2016.
    PubMed     Text format     Abstract available


    June 2017
  47. ELLINGSON BM, Gerstner E, Smits M, Huang RY, et al
    Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials.
    Clin Cancer Res. 2017 Jun 27. pii: clincanres.2844.2016.
    PubMed     Text format     Abstract available


  48. COOK SANGAR ML, Genovesi LA, Nakamoto MW, Davis MJ, et al
    Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.2943.2016.
    PubMed     Text format     Abstract available


    May 2017
  49. GEOERGER B, Bourdeaut F, DuBois SG, Fischer M, et al
    A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
    Clin Cancer Res. 2017;23:2433-2441.
    PubMed     Text format     Abstract available


  50. SLANEY CY, von Scheidt B, Davenport AJ, Beavis PA, et al
    Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
    Clin Cancer Res. 2017;23:2478-2490.
    PubMed     Text format     Abstract available


    April 2017
  51. BAKAS S, Akbari H, Pisapia J, Martinez-Lage M, et al
    In vivo detection of EGFRvIII in glioblastoma via perfusion magnetic resonance imaging signature consistent with deep peritumoral infiltration: the phi index.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1871.2016.
    PubMed     Text format     Abstract available



  52. Correction: Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.
    Clin Cancer Res. 2017;23:2127.
    PubMed     Text format    


  53. BATICH KA, Reap EA, Archer GE, Sanchez-Perez L, et al
    Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
    Clin Cancer Res. 2017;23:1898-1909.
    PubMed     Text format     Abstract available


  54. BI WL, Horowitz P, Greenwald NF, Abedalthagafi M, et al
    Landscape of Genomic Alterations in Pituitary Adenomas.
    Clin Cancer Res. 2017;23:1841-1851.
    PubMed     Text format     Abstract available


    March 2017

  55. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed     Text format    


    February 2017
  56. BLOCH O, Lim M, Sughrue ME, Komotar RJ, et al
    Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.1369.2016.
    PubMed     Text format     Abstract available


    January 2017
  57. RING EK, Markert JM, Gillespie GY, Friedman GK, et al
    Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.
    Clin Cancer Res. 2017;23:342-350.
    PubMed     Text format     Abstract available


    December 2016
  58. HOLDHOFF M, Guner G, Rodriguez FJ, Hicks JL, et al
    Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization.
    Clin Cancer Res. 2016 Dec 29. pii: clincanres.1490.2016.
    PubMed     Text format     Abstract available


  59. PORTNOW J, Synold TW, Badie B, Tirughana R, et al
    Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1518.2016.
    PubMed     Text format     Abstract available


    November 2016
  60. WANG Z, Hao Y, Zhang CB, Wang Z, et al
    The landscape of viral expression reveals clinically relevant viruses with potential capability of promoting malignancy in lower grade glioma.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.1495.2016.
    PubMed     Text format     Abstract available


  61. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Text format     Abstract available


    October 2016
  62. ELLIOTT JT, Marra K, Evans LT, Davis SC, et al
    Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism and EGFR expression for optically guided identification of orthotopic glioma.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1400.2016.
    PubMed     Text format     Abstract available


  63. KICKINGEREDER P, Gotz M, Muschelli J, Wick A, et al
    Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  64. STEEG PS, Zimmer AS, Gril B
    Therapeutics for Brain Metastases, Version 3.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.2035.2016.
    PubMed     Text format     Abstract available


    September 2016
  65. RAMACHANDRAN M, Yu D, Dyczynski M, Baskaran S, et al
    Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus.
    Clin Cancer Res. 2016 Sep 16. pii: clincanres.0925.2016.
    PubMed     Text format     Abstract available


  66. POINTER KB, Clark PA, Eliceiri KW, Salamat MS, et al
    Non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients.
    Clin Cancer Res. 2016 Sep 15. pii: clincanres.3169.2016.
    PubMed     Text format     Abstract available


    August 2016
  67. LIN F, de Gooijer MC, Hanekamp D, Chandrasekaran G, et al
    PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.1276.2016.
    PubMed     Text format     Abstract available


  68. CALINESCU AA, Yadav VN, Carballo E, Kadiyala P, et al
    Survival and proliferation of neural progenitor derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine positive feedback mechanism.
    Clin Cancer Res. 2016 Aug 19. pii: clincanres.2888.2015.
    PubMed     Text format     Abstract available


  69. WINKLER F, Osswald M, Blaes J, Liao Y, et al
    Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1327.2016.
    PubMed     Text format     Abstract available


  70. REINARTZ R, Wang S, Kebir S, Silver DJ, et al
    FUNCTIONAL SUBCLONE PROFILING FOR PREDICTION OF TREATMENT-INDUCED INTRA-TUMOR POPULATION SHIFTS AND DISCOVERY OF RATIONAL DRUG COMBINATIONS IN HUMAN GLIOBLASTOMA.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.2089.2015.
    PubMed     Text format     Abstract available


  71. LOWENSTEIN PR, Castro MG
    Multiple expressed endogenous glioma epitopes as novel vaccines for gliomas.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1477.2016.
    PubMed     Text format     Abstract available


    July 2016
  72. BALLARD P, Yates JW, Yang Z, Kim DW, et al
    Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0399.2015.
    PubMed     Text format     Abstract available


    June 2016
  73. KIM JE, Patel MA, Mangraviti A, Kim ES, et al
    Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas.
    Clin Cancer Res. 2016 Jun 29. pii: clincanres.1535.2015.
    PubMed     Text format     Abstract available


  74. KALININA J, Ahn J, Devi NS, Wang L, et al
    Selective detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of glioma patients with mutated Isocitrate Dehydrogenase.
    Clin Cancer Res. 2016 Jun 23. pii: clincanres.2965.2015.
    PubMed     Text format     Abstract available


  75. NIESSNER H, Schmitz J, Tabatabai G, Schmid A, et al
    PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo.
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.0064.2016.
    PubMed     Text format     Abstract available


  76. GENG F, Cheng X, Wu X, Yoo JY, et al
    Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis.
    Clin Cancer Res. 2016 Jun 8. pii: clincanres.2973.2015.
    PubMed     Text format     Abstract available


    May 2016
  77. LYLE LT, Lockman PR, Adkins CE, Mohammad AS, et al
    Alterations in Pericyte Subpopulations are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
    Clin Cancer Res. 2016 May 31. pii: clincanres.1836.2015.
    PubMed     Text format     Abstract available


  78. RAMPLING R, Peoples S, Mulholland PJ, James A, et al
    A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multi Peptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.
    Clin Cancer Res. 2016 May 25. pii: clincanres.0506.2016.
    PubMed     Text format     Abstract available


  79. OLOW A, Mueller S, Yang X, Hashizume R, et al
    BRAF status in personalizing treatment approaches for pediatric gliomas.
    Clin Cancer Res. 2016 May 23. pii: clincanres.1101.2015.
    PubMed     Text format     Abstract available


  80. XU R, Shimizu F, Hovinga K, Beal K, et al
    Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.
    Clin Cancer Res. 2016 May 6. pii: clincanres.0048.2016.
    PubMed     Text format     Abstract available


  81. WICK W, Gorlia T, Bady P, Platten M, et al
    Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082).
    Clin Cancer Res. 2016 May 3. pii: clincanres.3153.2015.
    PubMed     Text format     Abstract available



  82. Correction: Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
    Clin Cancer Res. 2016;22:2313.
    PubMed     Text format    


    April 2016
  83. TATEISHI K, Iafrate AJ, Ho Q, Curry WT, et al
    Myc-driven glycolysis is a therapeutic target in glioblastoma.
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.2274.2015.
    PubMed     Text format     Abstract available


    March 2016
  84. LUN X, Wells JC, Grinshtein N, King JC, et al
    Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of Glioblastoma.
    Clin Cancer Res. 2016 Mar 22. pii: clincanres.1798.2015.
    PubMed     Text format     Abstract available


  85. YAO Y, Ye H, Qi Z, Mo L, et al
    B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  86. PALANICHAMY K, Thirumoorthy K, Kanji S, Gordon N, et al
    Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.2308.2015.
    PubMed     Text format     Abstract available


    February 2016
  87. CURRY WT, Gorrepati R, Piesche M, Sasada T, et al
    Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Anti-tumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
    Clin Cancer Res. 2016 Feb 12. pii: clincanres.2163.2015.
    PubMed     Text format     Abstract available


    December 2015
  88. KEBIR S, Fimmers R, Galldiks N, Schaefer N, et al
    Late Pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Clin Cancer Res. 2015 Dec 16. pii: clincanres.1334.2015.
    PubMed     Text format     Abstract available


  89. MARTUSCELLO RT, Vedam-Mai V, McCarthy DJ, Schmoll ME, et al
    A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma.
    Clin Cancer Res. 2015 Dec 2. pii: clincanres.0916.2015.
    PubMed     Text format     Abstract available


    November 2015
  90. MA Y, Tang N, Thompson RC, Mobley B, et al
    InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma.
    Clin Cancer Res. 2015 Nov 11. pii: clincanres.1677.2015.
    PubMed     Text format     Abstract available


  91. ANDRONESI OC, Loebel F, Bogner W, Marjanska M, et al
    Treatment response assessment in IDH-mutant glioma patients by non-invasive 3D functional Spectroscopic Mapping of 2-Hydroxyglutarate.
    Clin Cancer Res. 2015 Nov 3. pii: clincanres.0656.2015.
    PubMed     Text format     Abstract available


    October 2015
  92. HUANG RY, Rahman R, Ballman KV, Felten S, et al
    The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.3040.2014.
    PubMed     Text format     Abstract available


  93. JACKSON CM, Kochel CM, Nirschl CJ, Durham NM, et al
    Systemic Tolerance Mediated by Melanoma Brain Tumors is Reversible by Radiotherapy and Vaccination.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1516.2015.
    PubMed     Text format     Abstract available


  94. VERREAULT M, Schmitt C, Goldwirt L, Pelton K, et al
    Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas.
    Clin Cancer Res. 2015 Oct 19. pii: clincanres.1015.2015.
    PubMed     Text format     Abstract available


  95. MAR N, Desjardins A, Vredenburgh JJ
    CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma-The Progress and the Limitations.
    Clin Cancer Res. 2015;21:4248-50.
    PubMed     Text format     Abstract available


    September 2015
  96. PHAM CD, Flores C, Yang C, Pinheiro EM, et al
    Differential immune microenvironments and response to immune checkpoint blockade amongst molecular subtypes of murine medulloblastoma.
    Clin Cancer Res. 2015 Sep 24. pii: clincanres.0713.2015.
    PubMed     Text format     Abstract available



  97. Correction: PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas.
    Clin Cancer Res. 2015;21:4243.
    PubMed     Text format    


    July 2015
  98. SINGH SK, Venugopal C, Hallett R, Vora P, et al
    Pyrvinium targets CD133 in human glioblastoma brain tumor-initiating cells.
    Clin Cancer Res. 2015 Jul 7. pii: clincanres.3147.2014.
    PubMed     Text format     Abstract available


    June 2015
  99. KIM SJ, Lee HJ, Kim SW, Choi HJ, et al
    Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice.
    Clin Cancer Res. 2015 Jun 23. pii: clincanres.3195.2014.
    PubMed     Text format     Abstract available


  100. HANNIFORD D, Zhong J, Koetz L, Gaziel-Sovran A, et al
    A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis.
    Clin Cancer Res. 2015 Jun 18. pii: clincanres.2566.2014.
    PubMed     Text format     Abstract available


  101. BROWN CE, Badie B, Barish ME, Weng L, et al
    Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T cells in Patients with Recurrent Glioblastoma.
    Clin Cancer Res. 2015 Jun 9. pii: clincanres.0428.2015.
    PubMed     Text format     Abstract available


    May 2015
  102. SHI Y, Chen C, Yu S, Liu Q, et al
    miR-663 suppresses oncogenic function of CXCR4 in glioblastoma.
    Clin Cancer Res. 2015 May 28. pii: clincanres.2807.2014.
    PubMed     Text format     Abstract available


    March 2015
  103. KLUGER H, Zito CR, Barr M, Baine M, et al
    Characterization of PD-L1 Expression and Associated T cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
    Clin Cancer Res. 2015 Mar 18. pii: clincanres.3073.2014.
    PubMed     Text format     Abstract available


    February 2015
  104. CARVAJAL RD, Lawrence DP, Weber J, Gajewski TF, et al
    Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
    Clin Cancer Res. 2015 Feb 18. pii: clincanres.1630.2014.
    PubMed     Text format     Abstract available


    January 2015
  105. HOFER S, Mengele K, Schmitt M, Pestalozzi B, et al
    Complement activation and rituximab distribution in CNS NHL--letter.
    Clin Cancer Res. 2015;21:490.
    PubMed     Text format    


  106. MORENO L, Marshall LV, Pearson AD, Morland B, et al
    A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
    Clin Cancer Res. 2015;21:267-73.
    PubMed     Text format     Abstract available


  107. MERINO DM, Shlien A, Villani A, Pienkowska M, et al
    Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups.
    Clin Cancer Res. 2015;21:184-92.
    PubMed     Text format     Abstract available


    May 2014
  108. CHEN G, Chakravarti N, Aardalen K, Lazar AJ, et al
    Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target.
    Clin Cancer Res. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: